BioSpace News Archive

InnerScope Hearing Technologies Inc. (OTC: INND) (“InnerScope”), an emerging and disruptive leader in the Over-the-Counter (OTC) Hearing Aid space today announced it had signed a Memorandum of Understanding (“MOU”) with NUHEARA Limited (ASX: NUH) (“NUHEARA”), a Medical device and consumer electronics manufacturer listed on the Australian Stock Market.

Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging systems and clinical services company, is pleased to announce the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device.

Mizuho OSI®, a leading manufacturer of specialty surgical tables and pressure injury abatement solutions has been recognized by The California Council for Excellence as one of only three silver level recipients of the California Awards for Performance Excellence.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN).

Eyenovia, Inc. (NASDAQ: EYEN) today announced that the company will participate at the 2023 International Consumer Electronics Show, which is being held January 5-8 at the Las Vegas Convention Center.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced another patient was dosed in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the sixteenth patient dosed with IMX-110 to-date, and the second patient dosed so far in December 2022.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the first patient in the HERKULES-1 Phase 1b trial evaluating ERK1/2 inhibitor ERAS-007 in combination with SHP2 inhibitor ERAS-601 (together, Erasca’s first MAPKlamp) in patients with RAS/MAPK pathway-altered solid tumors.

Day One Biopharmaceuticals today announced that Dr. Jeremy Bender, chief executive officer, will present during the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.

Seagen Inc. (Nasdaq:SGEN) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Time.

MAIA Biotechnology, Inc. (NYSE American: MAIA ) (“MAIA,” “the Company”) today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the planned U.S. expansion of the THIO-101 Phase 2 trial evaluating THIO, an investigational telomere-targeting agent, in patients with advanced non-small cell lung cancer (NSCLC).